[Federal Register Volume 76, Number 243 (Monday, December 19, 2011)]
[Notices]
[Pages 78670-78671]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-32368]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-D-0817]
Draft Guidance for Industry and Food and Drug Administration
Staff; Evaluation of Sex Differences in Medical Device Clinical
Studies; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of the draft guidance entitled ``Evaluation of Sex
Differences in Medical Device Clinical Studies.'' This document
provides guidance on the study and evaluation of sex differences in
medical device clinical trials, with a specific focus on addressing
potential differences in study design, conduct, outcomes, and
interpretation that should be considered to ensure sex-specific issues
are adequately addressed in clinical trials. This draft guidance is not
final nor is it in effect at this time.
DATES: Although you can comment on any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency considers your comment of this
draft guidance before it begins work on the final version of the
guidance, submit either electronic or written comments on the draft
guidance by March 19, 2012.
ADDRESSES: Submit written requests for single copies of the draft
guidance document entitled ``Evaluation of Sex Differences in Medical
Device Clinical Studies'' to the Division of Small Manufacturers,
International, and Consumer Assistance, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 4613, Silver Spring, MD 20993-0002. Send one self-
addressed adhesive label to assist that office in processing your
request, or fax your request to (301) 847-8149. See the SUPPLEMENTARY
INFORMATION section for information on electronic access to the
guidance.
Submit electronic comments on the draft guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852. Identify comments with the docket number
found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Kathryn O'Callaghan, Center for
Devices and Radiological Health, Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 66, Rm. 1546, Silver Spring, MD 20993-0002,
(301) 796-6349.
SUPPLEMENTARY INFORMATION:
I. Background
The purpose of this guidance is to outline the Center for Devices
and Radiological Health's (CDRH's) expectations regarding sex-specific
patient enrollment, data analysis, and reporting of study information.
The intent is to improve the quality and consistency of available data
regarding the performance of medical devices in women. This information
can be of benefit to patients and their medical providers, as well as
clinical researchers and others. The specific objectives of this
guidance are to: (1) Better communicate the balance of risks and
benefits of FDA-approved or cleared medical devices; (2) identify sex-
specific questions for further study; and (3) encourage the
consideration of sex and associated covariates (e.g., body size, plaque
morphology, etc.) during the trial design stage.
II. Significance of Guidance
This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the Agency's current thinking on ``Evaluation
of Sex Differences in Medical Device Clinical Studies.'' It does not
create or confer any rights for or on any person and does not operate
to bind FDA or the public. An alternative approach may be used if such
approach satisfies the requirements of the applicable statute and
regulations.
III. Electronic Access
Persons interested in obtaining a copy of the draft guidance may do
so by using the Internet. A search capability for all CDRH guidance
documents is available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm. Guidance
documents are also available at http://www.regulations.gov. To receive
``Evaluation of Sex Differences in Medical Device Clinical Studies,''
you may either send an email request to [email protected] to receive
an electronic copy of the document or send a fax request to (301) 847-
8149 to receive a hard copy. Please use the document number 1727 to
identify the guidance you are requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to currently approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in 21 CFR 812.25(c) have been approved under
OMB control number 0910-0078; the collections of information in 21 CFR
part 807 Subpart E have been approved under OMB control number 0910-
0120; the collections of information in 21 CFR part 814 Subparts B and
E have been approved under OMB control number 0910-0231; the
collections of information in 21 CFR part 814 Subpart H have been
approved under OMB control number 0910-0332; the collections of
information in 21 CFR part 822 have been approved under OMB control
number 0910-0449.
V. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) either electronic or written comments regarding this
document. It is only necessary to send one set of comments. It is no
longer necessary to send two copies of mailed comments.
[[Page 78671]]
Identify comments with the docket number found in brackets in the
heading of this document. Received comments may be seen in the Division
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: December 13, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-32368 Filed 12-16-11; 8:45 am]
BILLING CODE 4160-01-P